Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protein Design Labs

Executive Summary

Acquires rights to six monoclonal antibodies from Sandoz. Two of the MAbs, one for the treatment of cytomegalovirus and one for hepatitis B, have completed Phase I/II clinical trials. Two others -- for herpes simplex and varicella zoster viruses -- are in preclinical studies. The final two, which are both for epithelial cancers, were originally humanized from mouse antibodies by PDL for Sandoz; one has completed Phase I/II. PDL is paying Sandoz $5 mil. and could pay an additional $5 mil. in milestone payments. PDL says that "Sandoz has certain copromotion and comarketing rights and will earn royalties on PDL product sales in countries where it does not sell those products with PDL".
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022474

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel